A London company that provides AI software to the biopharmaceutical and healthcare industry has appointed Simon Coulthard as its new CFO.
Pangaea Data has also appointed Professor Mark Musen, Dr. Rick Sax and Ozgur Tuncer to its Scientific Advisory Board (SAB).
Coulthard joins Pangaea from Congenica, a digital health company spun out of the Wellcome Sanger Institute, where he was instrumental in a recent $50m Series C funding round.
The company says he will leverage a decade of international experience in software development and the recent global growth in Congenica’s digital health platform to accelerate expansion into Pangaea’s key strategic markets within the US healthcare and pharmaceutical industry.
https://businesscloud.co.uk/biotech-behind-covid-19-tracking-to-float-in-london/
Professor Musen is a professor of Biomedical Informatics and Director of the Stanford Centre for Biomedical Informatics Research at Stanford University. He chaired the Health Informatics and Modeling Topic Advisory Group for the World Health Organisation’s revision of the International Classification of Diseases, and is also principal investigator of the Center for Expanded Data Annotation and Retrieval (CEDAR).
Dr Sax was previously a Senior Vice President at IQVIA and formerly a Clinical Vice-President at AstraZeneca. He has established himself as an expert on drug research and development, advising UK and US venture capitalists on the risk perspective of pharmaceutical investments and asset development strategies.
Tuncer is Global Vice President, Financial Institutions at IQVIA and Investment Partner at Ascension Life Sciences Fund. He advises senior decision makers in the biopharmaceutical industry across Europe, USA and Middle East, focusing on M&A, valuations and portfolio management.
“I am delighted to join the team at Pangaea. The work they have been doing using AI to extract vital information from doctors’ notes, discharge summaries and other sources is revolutionising how the pharmaceutical industry finds cohorts for drug trials, taking a process that usually takes several months down to a few weeks,” said Coulthard.
“The connections they have already established with key players in the pharmaceutical market clearly demonstrate their unique offering.
“I look forward to working with the leadership team to further scale the business and achieve increasing recurring revenues as their platform is used for multiple applications across an enterprise.”
https://businesscloud.co.uk/can-biotech-halt-disease-which-has-led-to-slaughter-of-300000-cattle/
Dr Vibhor Gupta, founder and CEO of Pangaea, added: “The additions of Mr Simon Coulthard, Professor Musen, Dr Rick Sax and Mr Ozgur Tuncer to our team will have a significant impact on the growth of our company. Their combined industry experiences of more than 60 years and global network are unparalleled.
“At a time when our novel AI is being embedded within the core life sciences infrastructure, their knowledge will be invaluable to help us scale and expand in new markets.”